Chronic Obstructive Pulmonary Disease – Access & Reimbursement – Access & Reimbursement – Chronic Obstructive Pulmonary Disease (US)
The dynamics within the LAMA, LABA/LAMA, LABA/ICS FDC, and LABA/LAMA/ICS FDC drug classes will continue to shape the U.S. COPD market, as will the market entry of Verona’s nebulized PDE-3/PDE-4 inhibitor Ohtuvayre and multiple biologics, including Sanofi / Regeneron’s IL-4 / IL-13 inhibitor Dupixent. The dominance of branded LABA/ICS FDCs (e.g., GlaxoSmithKline’s Advair, AstraZeneca’s Symbicort) will likely decline further as new generic / branded generic agents continue to launch. In addition, the earlier-line use of LABA/LAMA/ICS FDCs will create uptake challenges for Boehringer Ingelheim’s Spiriva. Ohtuvayre could compete with existing LAMA and LABA/LAMA therapies for certain subpopulations with moderate to severe COPD, while Dupixent could provide a treatment option for severe COPD patients on maximal inhaled therapy. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current and emerging COPD agents will face increasing challenges as they strive to retain / gain favorable formulary position and market uptake.
QUESTIONS ANSWERED
- Which key COPD therapies (e.g., GSK’s Trelegy, Boehringer Ingelheim’s Stiolto) have favorable formulary placement, and how do payers manage the use and costs of these therapies?
- How do reimbursement restrictions affect physicians’ prescribing of LABA/ICS FDCs, Spiriva, LABA/LAMA/ICS FDCs, and Dupixent for COPD?
- How do physicians anticipate using GSK’s Nucala, Sanofi / Regeneron’s itepekimab, and Chiesi’s tanimilast for COPD, and how do payers expect to cover these therapies on commercial plans?
PRODUCT DESCRIPTION
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
- Evaluate competitor strategies for securing favorable market access terms.
Primary research: Survey of 140 U.S. primary care physicians and pulmonologists; survey of 30 U.S. managed care organization pharmacy and medical directors
Fingertip Formulary: Formulary coverage by commercial plans covering more than 165 million lives nationally and Medicare Part D plans covering up to 37.5 million lives.
Real-world data: U.S. pharmacy and medical claims data
Key drugs: Trelegy, Spiriva, Stiolto, Breztri, Dupixent, Symbicort, Anoro, Advair, Ohtuvayre, Nucala, itepekimab, tanimilast.
